Bryon D. Johnson, PhD

Professor, Pediatrics (Hematology/Oncology/BMT) and Microbiology & Immunology

Locations

Microbiology & Immunology

Contact Information

General Interests

Cancer immunology and immunotherapy

Education

PhD, Immunology, University of Health Sciences/The Chicago Medical School (now Rosalind Franklin University), 1989
BS, Microbiology, Iowa State University, 1983

Research Interests

I am interested in understanding the biology and immunology of cancer, and uncovering novel immune-based approaches to treat cancer. My current research focuses on combining the following approaches to improve the use of cancer immunotherapy for treating both solid tumors and hematologic cancers: (1) immune checkpoint protein blockade, (2) adoptive transfer of cancer-reactive T lymphocytes, and (3) the use of metabolic inhibitors to increase T cell immunity.

The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation.

(Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM.) Brain Behav Immun Health. 2022 Aug;23:100480 PMID: 35757656 PMCID: PMC9213229 SCOPUS ID: 2-s2.0-85133379996 06/28/2022
Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies.

(Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN.) Cytotherapy. 2022 Aug;24(8):767-773 PMID: 35597752 SCOPUS ID: 2-s2.0-85130432792 05/22/2022
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.

(Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN.) JAMA Oncol. 2022 05 01;8(5):773-775 PMID: 35266965 PMCID: PMC8914887 SCOPUS ID: 2-s2.0-85126591538 03/11/2022
Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone.

(Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M.) Adv Sci (Weinh). 2022 04;9(12):e2101267 PMID: 35243806 PMCID: PMC9036031 SCOPUS ID: 2-s2.0-85125564839 03/05/2022
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.

(Mohammed A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, Johnson BD, Khleif SN, Pollak MN, Schlom J, Shoemaker RH, Stanton SE, Wondrak GT, You M, Zhu H, Miller MS.) J Cancer Prev. 2021 Dec 30;26(4):309-317 PMID: 35047458 PMCID: PMC8749317 01/21/2022
Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?

(Palen K, Zurko J, Johnson BD, Hari P, Shah NN.) Cytotherapy. 2021 11;23(11):985-990 PMID: 34538575 SCOPUS ID: 2-s2.0-85115015094 09/21/2021
PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response.

(Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN.) Haematologica. 2021 10 01;106(10):2788-2790 PMID: 33853295 PMCID: PMC8485669 SCOPUS ID: 2-s2.0-85116219490 04/16/2021
Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA.

(Pan J, Chen Y, Zhang Q, Khatun A, Palen K, Xin G, Wang L, Yang C, Johnson BD, Myers CR, Sei S, Shoemaker RH, Lubet RA, Wang Y, Cui W, You M.) Commun Biol. 2021 07 23;4(1):906 PMID: 34302042 PMCID: PMC8302676 SCOPUS ID: 2-s2.0-85111091265 07/25/2021
Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression.

(AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB.) iScience. 2021 Jun 25;24(6):102653 PMID: 34189432 PMCID: PMC8220235 07/01/2021
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

(Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A.) J Cancer Prev. 2021 Mar 30;26(1):71-82 PMID: 33842408 PMCID: PMC8020174 04/13/2021
Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression

(AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB.) iScience. 25 June 2021;24(6) SCOPUS ID: 2-s2.0-85107963806 06/25/2021
STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.

(Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, Johnson BD, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2021;12(1):41-58 PMID: 33548597 PMCID: PMC8081932 SCOPUS ID: 2-s2.0-85104314508 02/07/2021

Bryon D. Johnson, PhD